Literature DB >> 29057546

Clinical features and biological implications of different U2AF1 mutation types in myelodysplastic syndromes.

Bing Li1,2, Jinqin Liu2, Yujiao Jia3, Jingya Wang1, Zefeng Xu1,2, Tiejun Qin1, Zhongxun Shi1, Zhen Song4, Shuailing Peng1, Huijun Huang1, Liwei Fang1, Hongli Zhang1, Lijuan Pan1, Naibo Hu1, Shiqiang Qu1, Yue Zhang1,2, Jian Wu5, Na Liu5, Kun Ru3, Gang Huang6, Zhijian Xiao1,2.   

Abstract

U2AF1 mutations (U2AF1MT) occur commonly in myelodysplastic syndromes (MDS) without ring sideroblasts. The aim of this study was to investigate the clinical and biological implications of different U2AF1 mutation types in MDS. We performed targeted gene sequencing in a cohort of 511 MDS patients. Eighty-six patients (17%) were found to have U2AF1MT, which occurred more common in younger patients (P = .001) and represented ancestral lesions in a substantial proportion (71%) of cases. ASXL1MT and isolated +8 were significantly enriched in U2AF1MT-positive cases, whereas TP53MT, SF3B1MT, and complex karyotypes were inversely associated with U2AF1MT. U2AFS34 subjects were enriched for isolated +8 and were inversely associated with complex karyotypes. U2AF1MT was significantly associated with anemia, thrombocytopenia, and poor survival in both lower-risk and higher-risk MDS. U2AF1S34 subjects had more frequently platelet levels of <50 × 109 /L (P = .043) and U2AF1Q157 /U2AF1R156 subjects had more frequently hemoglobin concentrations at <80 g/L (P = .008) and more often overt fibrosis (P = .049). In conclusion, our study indicates that U2AF1MT is one of the earliest genetic events in MDS patients and that different types of U2AF1MT have distinct clinical and biological characteristics.
© 2017 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29057546      PMCID: PMC9204509          DOI: 10.1002/gcc.22510

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   4.263


  44 in total

1.  Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.

Authors:  P Silva; M Neumann; M P Schroeder; S Vosberg; C Schlee; K Isaakidis; J Ortiz-Tanchez; L R Fransecky; T Hartung; S Türkmen; A Graf; S Krebs; H Blum; C Müller-Tidow; C Thiede; G Ehninger; H Serve; J Hecht; W E Berdel; P A Greif; C Röllig; C D Baldus
Journal:  Leukemia       Date:  2017-04-03       Impact factor: 11.528

Review 2.  Stem cell origin of myelodysplastic syndromes.

Authors:  H K Elias; C Schinke; S Bhattacharyya; B Will; A Verma; U Steidl
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

3.  Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo.

Authors:  Cara Lunn Shirai; James N Ley; Brian S White; Sanghyun Kim; Justin Tibbitts; Jin Shao; Matthew Ndonwi; Brian Wadugu; Eric J Duncavage; Theresa Okeyo-Owuor; Tuoen Liu; Malachi Griffith; Sean McGrath; Vincent Magrini; Robert S Fulton; Catrina Fronick; Michelle O'Laughlin; Timothy A Graubert; Matthew J Walter
Journal:  Cancer Cell       Date:  2015-05-11       Impact factor: 31.743

4.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

5.  [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].

Authors:  Shi-qiang Qu; Xu-ping Liu; Ze-feng Xu; Yue Zhang; Tie-jun Qin; Tian-jiao Zhang; Rui Cui; Yu-shu Hao; Zhi-jian Xiao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2011-12

6.  Age-related mutations associated with clonal hematopoietic expansion and malignancies.

Authors:  Mingchao Xie; Charles Lu; Jiayin Wang; Michael D McLellan; Kimberly J Johnson; Michael C Wendl; Joshua F McMichael; Heather K Schmidt; Venkata Yellapantula; Christopher A Miller; Bradley A Ozenberger; John S Welch; Daniel C Link; Matthew J Walter; Elaine R Mardis; John F Dipersio; Feng Chen; Richard K Wilson; Timothy J Ley; Li Ding
Journal:  Nat Med       Date:  2014-10-19       Impact factor: 53.440

7.  Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome.

Authors:  Cara Lunn Shirai; Brian S White; Manorama Tripathi; Roberto Tapia; James N Ley; Matthew Ndonwi; Sanghyun Kim; Jin Shao; Alexa Carver; Borja Saez; Robert S Fulton; Catrina Fronick; Michelle O'Laughlin; Chandraiah Lagisetti; Thomas R Webb; Timothy A Graubert; Matthew J Walter
Journal:  Nat Commun       Date:  2017-01-09       Impact factor: 14.919

Review 8.  Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions.

Authors:  Ali N Chamseddine; Elias Jabbour; Hagop M Kantarjian; Zachary S Bohannan; Guillermo Garcia-Manero
Journal:  Curr Oncol Rep       Date:  2016-01       Impact factor: 5.945

9.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.

Authors:  T Haferlach; Y Nagata; V Grossmann; Y Okuno; U Bacher; G Nagae; S Schnittger; M Sanada; A Kon; T Alpermann; K Yoshida; A Roller; N Nadarajah; Y Shiraishi; Y Shiozawa; K Chiba; H Tanaka; H P Koeffler; H-U Klein; M Dugas; H Aburatani; A Kohlmann; S Miyano; C Haferlach; W Kern; S Ogawa
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528

10.  Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.

Authors:  Stanley Chun-Wei Lee; Heidi Dvinge; Eunhee Kim; Hana Cho; Jean-Baptiste Micol; Young Rock Chung; Benjamin H Durham; Akihide Yoshimi; Young Joon Kim; Michael Thomas; Camille Lobry; Chun-Wei Chen; Alessandro Pastore; Justin Taylor; Xujun Wang; Andrei Krivtsov; Scott A Armstrong; James Palacino; Silvia Buonamici; Peter G Smith; Robert K Bradley; Omar Abdel-Wahab
Journal:  Nat Med       Date:  2016-05-02       Impact factor: 53.440

View more
  20 in total

Review 1.  Therapeutic approaches to treat human spliceosomal diseases.

Authors:  Anthony B DeNicola; Yi Tang
Journal:  Curr Opin Biotechnol       Date:  2019-02-15       Impact factor: 9.740

2.  Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.

Authors:  Naoki Shingai; Yuka Harada; Hiroko Iizuka; Yosuke Ogata; Noriko Doki; Kazuteru Ohashi; Masao Hagihara; Norio Komatsu; Hironori Harada
Journal:  Int J Hematol       Date:  2018-10-23       Impact factor: 2.490

3.  Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident.

Authors:  Larysa Poluben; Maneka Puligandla; Donna Neuberg; Christine R Bryke; Yahsuan Hsu; Oleksandr Shumeiko; Xin Yuan; Olga Voznesensky; German Pihan; Miriam Adam; Ernest Fraenkel; Roni Rasnic; Michal Linial; Sergiy Klymenko; Steven P Balk; Paula G Fraenkel
Journal:  Am J Hematol       Date:  2018-10-31       Impact factor: 10.047

4.  Mutational features of myelodysplastic syndromes with Auer rods reveal them are more akin to acute myeloid leukemia.

Authors:  Huijun Huang; Tiejun Qin; Zefeng Xu; Zhongxun Shi; Bing Li; Lijuan Pan; Naibo Hu; Shiqiang Qu; Gang Huang; Robert P Gale; Zhijian Xiao
Journal:  Br J Haematol       Date:  2019-12-27       Impact factor: 8.615

5.  Prognostic mutations in persons with isolated neutropenia myelodysplastic syndrome.

Authors:  Zhongxun Shi; Tiejun Qin; Zefeng Xu; Bing Li; Huijun Huang; Hongli Zhang; Liwei Fang; Lijuan Pan; Naibo Hu; Shiqiang Qu; Gang Huang; Robert Peter Gale; Zhijian Xiao
Journal:  Leuk Lymphoma       Date:  2019-05-06

6.  Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations.

Authors:  Shiqiang Qu; Bing Li; Tiejun Qin; Zefeng Xu; Lijuan Pan; Naibo Hu; Gang Huang; Robert Peter Gale; Zhijian Xiao
Journal:  Br J Haematol       Date:  2020-04-19       Impact factor: 8.615

7.  [Clonal evolution of myelodysplastic syndrome].

Authors:  B Q Luo; F Dong; M X F Ema
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-12-14

8.  [Mean corpuscular volume ≤100 fl was an independent prognostic factor in patients with myelodysplastic syndrome and bone marrow blast<5 percent].

Authors:  Z X Shi; T J Qin; Z F Xu; H J Huang; B Li; S Q Qu; N B Hu; L J Pan; D Liu; Y N Cai; Y D Zhang; Z J Xiao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-01-14

9.  [Clinical features and prognostic analysis of myelodysplastic syndromes patients with U2AF1 mutation].

Authors:  C Hou; S H Jiang; H J Shen; Z X Ding; M Miao; S N Chen; Y Xu; D P Wu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-01-14

10.  [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts].

Authors:  Y N Cai; Z F Xu; B Li; T J Qin; L J Pan; S Q Qu; N B Hu; D Liu; H J Huang; Z X Shi; Y D Zhang; Z J Xiao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.